ONCIMMUNE HOLDINGS ORD 1P overview

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 19 March 2019 Oncimmune Holdings plc ("Oncimmune" or the "Company") Oncimmune Announces the Acquisition of Protagen Diagnostics AG, a Leader in Personalised Immuno-Profiling...

Oncimmune Holdings plc (“Oncimmune” or the “Company”) Announces the Appointment of Marco Casarin as General Manager, Oncimmune USA LLC Nottingham, UK – 13 September 2018: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary Early CDT® liquid biopsy platform technology, today announces the appointment of Marco Casarin as General Manager, Oncimmune USA LLC. Marco has more than 25 years of global healthcare...

Launch of "Finger Stick" Sample Collection for EarlyCDT®-Lung Simplified blood sample collection procedure introduces ease of use and quicker results PR Newswire DESOTO, Kan., Nov. 9, 2017 DESOTO, Kan., Nov. 9, 2017 /PRNewswire/ -- Oncimmune USA LLC, the U.S. subsidiary of Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercializing its proprietary Early CDT® platform technology, today announces its launch of a validated finger stick collection...